Shenzhen Refresh Intelligent Electronics Co., Ltd. Files IPO Prospectus Highlighting Miniaturized Smart Biosensors for Health Monitoring
With the continuous advancement of biosensing technologies and semiconductors, human health monitoring and intervention methods are making rapid strides toward the molecular level. As the foundational hardware technology, biosensors are evolving toward miniaturization, precision, adaptability, and self-calibration.
As an early-stage startup in the field of smart biosensors, how does Shenzhen Refresh Intelligent Electronics Co., Ltd. (hereinafter referred to as “Refresh Intelligent”) view the commercial application of miniaturized smart biosensors? What technological arrangements has Refresh Intelligent made for commercial applications? In light of this, VCBeat conducted an exclusive interview with Refresh Intelligent, a builder of miniaturized health monitoring systems.
Refresh Intelligence is a technology platform company specializing in human vital sign monitoring based on biosensing technology. Yan Dan, CEO of Refresh Intelligence, stated, “There are two reasons why Refresh Intelligence leverages smart biosensors to achieve human health management: First, preventive medicine is the primary approach to future health management, and a key prerequisite for prevention is the digital monitoring and control of health processes; Second, it can, to some extent, alleviate the contradiction between limited hospital resources and the enormous demand for patient health management.”
“Over the past five to eight years, the commercial market value of daily health management has been very limited due to the bulkiness or low portability of traditional devices, which prevented real-time, continuous monitoring. Reviewing the development history of consumer electronics such as computers and cameras, we see that the miniaturization of integrated circuits has virtually transformed human lifestyles. We have every reason to believe that miniaturized smart biosensor electronic devices have the potential to revolutionize traditional hospital testing methods. As miniaturized applications penetrate various scenarios, their market impact will accumulate and explode in a short period.”
“On the other hand, in the future era of the digital economy, health data will be a crucial component of this economic cycle. In the past, due to spatial and temporal constraints, hospital testing data could not be utilized for daily health management. The miniaturized biosensing devices we have developed enable health quantification through large-scale digital trend statistics and feedback from users.”
Shenzhen Refresh Biosensor Technology Co., Ltd.’s independently developed custom biosensor development platform primarily comprises a base layer and a bio-layer. The base layer is an integrated circuit digital processing system centered on proprietary biochips, while the bio-layer consists of biological materials tailored to specific analytes.
Currently, through multiple proprietary technologies including biochips, integrated biosensing electrodes, and data interaction systems, real-time monitoring can be achieved for a variety of substances, such as lactate, glucose, potassium ions, sodium ions, uric acid, urinary glucose, urinary ketones, body temperature, skin moisture, pH level, alcohol, carbon dioxide, and carbon monoxide.
Yan Dan explained, “By leveraging core foundational layer technologies, detection techniques adapted to different biological layers can enable the detection of various molecules. For instance, sweat-analysis wristbands can detect glucose and lactate. When the biosensing solution is configured for uric acid detection, the system can be adapted with uric acid-specific sensing materials to achieve urine monitoring.”
"Meanwhile, we have also deployed a multi-channel data acquisition system that enables the parallel use of multiple sensors." Yan Dan introduced that the multi-channel data acquisition system is composed of matrix sensors, which enhance the accuracy of decision-making mechanisms through multidimensional detection data.
(Image provided by the company)
“In terms of commercial applications, our platform supports a variety of output solutions for human vital signs monitoring scenarios, such as smart wearable devices, precision medicine, intelligent in-vehicle human vital signs monitoring, and personnel engaged in special operations.”
Regarding the advantages of the core platform, Yan Dan stated, “First, biosensing technology is a highly interdisciplinary field, and our company’s core team comprises senior researchers from various disciplines. Second, our independently developed second-generation MS02 biochip, as the centerpiece of the platform, integrates data storage and self-calibration capabilities while achieving high-precision measurement ranges, thereby establishing a core competitive advantage in its applications.”
As a technology-exporting enterprise, Refresh Intelligence must have a robust research and development team. Yan Dan introduced, “The Chief Scientist of Refresh Intelligence is Professor Zhang Xueji. At the age of 30, Professor Zhang was nominated for the Nobel Prize. Before returning to China, he received the United Nations ICSC-World Laboratory SIMON Award, becoming one of only two recipients worldwide that year.”
“He was also appointed as Senior Vice President of WPI in the United States, becoming the first foreign national to hold a senior vice presidential position at the company in over 40 years. Professor Zhang Xueji also serves as Chief Scientist for National Major Research Projects, Chief Scientist for National Key R&D Programs, and Guiding Expert for National Major Research Plans.”
“In recent years, Professor Zhang Xueji has led or participated in major national projects and research initiatives funded by agencies such as the U.S. NIH, NSF, NASA, and the Department of Defense, as well as China’s National Key R&D Program, the National Major Scientific Instrument Development Project, and the National Natural Science Foundation of China.”
“In addition to the Chief Scientist, our core team members have participated in major national projects such as the National Major Projects 01 and 02, and have led the development of multiple Class III active implantable medical devices characterized by precision and miniaturization. More than half of the team members possess over ten years of project development experience.”